Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOP-CABG: Ticagrelor De-escalation after CABG
NCT05380063Phase 4Completed
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Feb 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by National Center for Cardiovascular Disease. Primary endpoints: Great Saphenous Vein (SVG) Graft Occlusion Rate at 1 year and Bleeding Events at 1 year. Started Feb 2023; status: completed.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05380063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05380063.